RecruitingPhase 4NCT06848387

Unbound Cloxacillin Concentrations During Continuous Infusion

Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump


Sponsor

Emeli Månsson

Enrollment

25 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Unbound cloxacillin concentration for people with staphylococcal infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTUnbound cloxacillin concentration

Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.


Locations(1)

Västmanlands sjukhus Västerås

Västerås, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06848387


Related Trials